Advertisements



Sorrento Therapeutics expands clinical development of resiniferatoxin

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

Sangamo Therapeutics, Inc. (SGMO) Sangamo Clinical Development Update Conference Call (Transcript)

Sangamo Therapeutics, Inc. (SGMO) Sangamo Clinical Development Update Conference Call (Transcript).....»»

Category: topSource: seekingalphaApr 6th, 2019

The Wall Street Journal: Sorrento Therapeutics sues billionaire Soon-Shiong over development of cancer drug

Sorrento Therapeutics Inc. alleges billionaire Patrick Soon-Shiong and .....»»

Category: topSource: marketwatchApr 3rd, 2019

Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights

NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a late-stage clinical bioph.....»»

Category: earningsSource: benzingaMar 22nd, 2019

Analysts Laud Sarepta"s "Increasingly Active" Gene Therapy Clinical Development

Sarepta Therapeutics Inc (NASDAQ: SRPT) reported fourth-quarter results Wednesday alongside positive results for its muscular dystrophy gene therapy candidate. .....»»

Category: blogSource: benzingaFeb 28th, 2019

Sarepta doubles down on gene therapies after early Limb-Girdle data

As some biotechs struggle to meet the expectations placed upon gene therapies, Sarepta Therapeutics is investing further in the field, announcing a deal to purchase its development partner for $165 million after positive early clinical trial data. .....»»

Category: topSource: bizjournalsFeb 27th, 2019

ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019

Geneva, Switzerland and Boston, MA –February 27, 2019 - ObsEva SA (NASDAQ:OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman.....»»

Category: earningsSource: benzingaFeb 27th, 2019

Protagonist Therapeutics to begin clinical development of PN-10943

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 27th, 2018

Anchiano Therapeutics Reports Third Quarter 2018 Financial and Operational Results

CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced op.....»»

Category: earningsSource: benzingaNov 19th, 2018

Trillium Therapeutics Reports First Quarter 2018 Financial and Operating Results

Focusing TTI-621 clinical development on T.....»»

Category: earningsSource: benzingaMay 11th, 2018

Novus Therapeutics says OP0201 was "safe and well-tolerated" in clinical trials

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall6 hr. 3 min. ago

Applied Therapeutics IPO: Phase 2-3 Clinical Trial Should Commence In 2019

Applied Therapeutics IPO: Phase 2-3 Clinical Trial Should Commence In 2019.....»»

Category: topSource: seekingalphaApr 19th, 2019

Cidara selects first clinical development candidate from Cloudbreak program

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

Why Sorrento Therapeutics Is Jumping Today

Good news from a preclinical study is exciting investors about the potential for one of Sorrento's experimental drugs......»»

Category: topSource: foxnewsApr 10th, 2019

Sorrento Therapeutics announces top line results from Parkinson"s disease study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 10th, 2019

Here"s Why Sorrento Therapeutics Soared 134% in March

The early-stage biotech jumped without any significant news......»»

Category: topSource: foxnewsApr 9th, 2019

Immutep (IMMP) To Host Eftilagimod Alpha Clinical Development Update Global - Slideshow

Immutep (IMMP) To Host Eftilagimod Alpha Clinical Development Update Global - Slideshow.....»»

Category: topSource: seekingalphaApr 5th, 2019

Sorrento Therapeutics Is Not Happy

Sorrento Therapeutics Is Not Happy.....»»

Category: topSource: seekingalphaApr 5th, 2019

Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme

Biopharmaceutical company Sorrento Therapeutics Inc. has filed lawsuits against Dr. Patrick Soon-Shiong and his NantWorks network of companies, accusing the biotech entrepreneur of engaging in a “catch-and-kill” plan that ultimately blocked the r.....»»

Category: topSource: bizjournalsApr 4th, 2019

Sorrento Therapeutics sues Soon-Shiong, alleging it was shortchanged in cancer drug sale

A San Diego biopharmaceutical company is accusin.....»»

Category: topSource: latimesApr 4th, 2019

Jounce Therapeutics reports new clinical data on vopratelimab

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2019